Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC, 34874-34875 [2018-15719]

Download as PDF 34874 Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices filed. The Secretary will not accept a document for filing without a certificate of service. The Commission has determined that these reviews are extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C.1675(c)(5)(B). Authority: These reviews are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.62 of the Commission’s rules. Issued: July 18, 2018. By order of the Commission. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–15708 Filed 7–20–18; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–989 (Enforcement)] Certain Automated Teller Machines, ATM Modules, Components Thereof, and Products Containing the Same Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Enforcement Proceeding To Reflect a Corporate Name Change U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission (‘‘the Commission’’) has determined not to review an initial determination (‘‘ID’’) (Order No. 46) amending the complaint and Notice of Enforcement Proceeding to reflect a corporate name change. FOR FURTHER INFORMATION CONTACT: Ron Traud, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 202–205–3427. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (‘‘EDIS’’) at https:// edis.usitc.gov. Hearing-impaired amozie on DSK3GDR082PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 19:07 Jul 20, 2018 Jkt 244001 persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone 202–205–1810. On March 14, 2016, the Commission instituted the original investigation based on a complaint filed by Nautilus Hyosung Inc. (now Hyosung TNS Inc.) of Seoul, Republic of Korea, and Nautilus Hyosung America Inc. of Irving, Texas (collectively, ‘‘Nautilus’’). 81 FR 13149 (Mar. 14, 2016). Pertinent to this action, the complaint alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation into the United States, and the sale within the United States after importation of certain automated teller machines, ATM modules, components thereof, and products containing the same by reason of infringement of any of claims 1–3, 6, 8, and 9 of U.S. Patent No. 8,523,235 (‘‘the ’235 patent’’). Id. The complaint also alleged infringement of claims 1–3 and 5 of U.S. Patent No. 7,891,551; claims 1 and 6 of U.S. Patent No. 7,950,655; and claims 1–4, 6, and 7 of U.S. Patent No. 8,152,165. Those claims were subsequently terminated from the investigation. See Order No. 11 (June 30, 2016), Comm’n Notice of Non-Review (July 27, 2016); Order No. 17 (July 21, 2016), Comm’n Notice of Non-Review (August 16, 2016). The notice of institution of the investigation named Diebold Nixdorf, Incorporated and Diebold Self-Service Systems, both of North Canton, Ohio (collectively, ‘‘Diebold’’), as respondents. 81 FR 13149; 82 FR 13501 (Mar. 13, 2017). The Office of Unfair Import Investigations (‘‘OUII’’) was not named as a party. 81 FR 13149. On July 14, 2017, the Commission found a section 337 violation as to the ’235 patent and issued a limited exclusion order (‘‘LEO’’) as well as cease and desist orders (‘‘CDOs’’). 82 FR 33513 (July 20, 2017). The LEO prohibits the unlicensed entry of automated teller machines, ATM modules, components thereof, and products containing the same that infringe one or more of claims 1–3, 6, 8, and 9 of the ’235 patent that are manufactured by, or on behalf of, or are imported by or on behalf of Diebold Nixdorf, Incorporated, Diebold SelfService Systems, or any of their affiliated companies, parents, subsidiaries, agents, or other related business entities, or their successors or assigns. Id. The CDOs prohibit, among other things, the importation, sale, and SUPPLEMENTARY INFORMATION: PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 distribution of infringing products by Diebold. Id. On December 22, 2017, the Commission instituted the subject enforcement proceeding based on a complaint filed by Nautilus, alleging that Diebold violated the July 14, 2017, remedial orders issued in the original investigation and to determine what, if any, enforcement measures are appropriate. 82 FR 60762 (Dec. 22, 2017). Diebold is named as a respondent, and OUII is named as a party. Id. On June 22, 2018, the presiding administrative law judge issued Order No. 46, the subject ID, which granted an unopposed motion filed by Nautilus to amend the complaint and the Commission’s Notice of Enforcement Proceeding to reflect the corporate name change of Nautilus Hyosung Inc. to Hyosung TNS Inc. No petitions for review of the subject ID were filed. The Commission has determined not to review the subject ID. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: July 17, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–15615 Filed 7–20–18; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 22, 2018. Such persons may also file a written request for a hearing on the application on or before August 22, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement DATES: E:\FR\FM\23JYN1.SGM 23JYN1 34875 Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. Gamma Hydroxybutyric Acid. 2010 Schedule I The company plans to import finished dosage unit products containing gammahydroxybutyric acid for clinical trials, research, and analytical activities. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been delegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on June 18, 2018, Catalent Pharma Solutions, LLC, 3031 Red Lion Road, Philadelphia, Pennsylvania 19114, applied to be registered as an importer of the following basic class of controlled substance: SUPPLEMENTARY INFORMATION: Drug code Controlled substance Dated: July 12, 2018 John J. Martin, Assistant Administrator. [FR Doc. 2018–15719 Filed 7–20–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: VHG Labs DBA LGC Standards ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 22, 2018. Such persons may also file a written request for a hearing on the application on or before August 22, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia DATES: 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on April 13, 2018, VHG Labs DBA LGC Standards, 3 Perimeter Road, Manchaster NH 03103 applied to be registered as an importer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: amozie on DSK3GDR082PROD with NOTICES1 Controlled substance Drug code 3-Fluoro-N-methylcathinone (3-FMC) ...................................................................................................................... Cathinone ................................................................................................................................................................ Methcathinone ......................................................................................................................................................... 4-Fluoro-N-methylcathinone (4-FMC) ...................................................................................................................... Pentedrone (a-methylaminovalerophenone) ........................................................................................................... Mephedrone (4-Methyl-N-methylcathinone) ............................................................................................................ 4-Methyl-N-ethylcathinone (4-MEC) ........................................................................................................................ Naphyrone ............................................................................................................................................................... N-Ethylamphetamine ............................................................................................................................................... 4-Methylaminorex (cis isomer) ................................................................................................................................ Methaqualone .......................................................................................................................................................... JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ........................................................................................... SR-18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ........................................ APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide ...................................................... JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ........................................................................................... SR-19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole ............................................................. JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ...................................................................... JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) .............................................................................................. UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .......................................................... AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ............................................................................................... JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) .............................................................................................. Ibogaine ................................................................................................................................................................... Lysergic acid diethylamide ...................................................................................................................................... 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) ........................................................................................ Marihuana ................................................................................................................................................................ Mescaline ................................................................................................................................................................ 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2 ) .................................................................................... VerDate Sep<11>2014 19:07 Jul 20, 2018 Jkt 244001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\23JYN1.SGM 23JYN1 1233 1235 1237 1238 1246 1248 1249 1258 1475 1590 2565 6250 7008 7048 7081 7104 7118 7122 7144 7201 7203 7260 7315 7348 7360 7381 7385 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I

Agencies

[Federal Register Volume 83, Number 141 (Monday, July 23, 2018)]
[Notices]
[Pages 34874-34875]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15719]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Catalent Pharma 
Solutions, LLC

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before August 22, 2018. 
Such persons may also file a written request for a hearing on the 
application on or before August 22, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for 
hearing must be sent to: Drug Enforcement

[[Page 34875]]

Administration, Attn: Administrator, 8701 Morrissette Drive, 
Springfield, Virginia 22152. All request for hearing should also be 
sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug 
Enforcement Administration, Attn: DEA Federal Register Representative/
DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been delegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on June 
18, 2018, Catalent Pharma Solutions, LLC, 3031 Red Lion Road, 
Philadelphia, Pennsylvania 19114, applied to be registered as an 
importer of the following basic class of controlled substance:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid..............     2010  I
------------------------------------------------------------------------

    The company plans to import finished dosage unit products 
containing gamma-hydroxybutyric acid for clinical trials, research, and 
analytical activities.

    Dated: July 12, 2018
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-15719 Filed 7-20-18; 8:45 am]
 BILLING CODE 4410-09-P